Our results indicate that the combined use of a triplex microRNA panel based on the three miRNAs miR-21, miR-122 and miR-192 and AFP levels significantly improve HCC surveillance in HBV carriers, especially in LC patients with normal AFP levels or HCC patients with small tumor sizes. Here, AFP is linked to hepatocellular carcinoma.